Generalized Anxiety Disorder
📧 Sign up to get email alerts when something new happens for Generalized Anxiety Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2020-06-11Clinical Trial Update: Quetiapine SR and Divalproex Sodium ER in the Treatment of Anxiety in Bipolar Disorder With Panic Disorder and/or GAD [Phase 4]
Phase 4 clinical trial evaluating quetiapine XR with divalproex ER for anxiety symptoms in bipolar disorder patients with panic disorder and…
-
FDA approval · 2020-05-29FDA Approved: BUSPIRONE HYDROCHLORIDE — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
FDA approved a supplemental application for buspirone hydrochloride from Zydus Pharmaceuticals USA Inc.
-
FDA approval · 2020-05-29FDA Approved: BUSPIRONE HYDROCHLORIDE — Supplemental Application (Rising Pharma Holdings, Inc.)
The FDA approved a supplemental application for buspirone hydrochloride, approving a generic version from Rising Pharma Holdings, Inc.
-
FDA approval · 2020-05-28FDA Approved: BUSPIRONE HYDROCHLORIDE — Supplemental Application (Oxford Pharmaceuticals, LLC)
FDA approved a supplemental application for buspirone hydrochloride from Oxford Pharmaceuticals, LLC under the Abbreviated New Drug Applicat…
-
FDA approval · 2020-05-28FDA Approved: BUSPIRONE HCL — Supplemental Application (Advagen Pharma Ltd)
The FDA approved a supplemental application for Buspirone hydrochloride (Buspirone HCl) filed by Advagen Pharma Ltd under ANDA075521, adding…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2020-05-08Clinical Trial Update: Efficacy of Therapist Guided e-Therapy Versus Self-Help Therapy on Psychological Distress Among Individuals in Oman During COVID-19 Pandemic [Phase 3]
Phase 3 clinical trial evaluating therapist-guided e-therapy versus self-help therapy for psychological distress during COVID-19 in Oman; re…
-
FDA approval · 2020-04-20FDA Approved: CYMBALTA — Supplemental Application (Eli Lilly and Company)
FDA approved a supplemental application for Cymbalta (duloxetine hydrochloride) from Eli Lilly, granting updated labeling under the NDA.
-
FDA approval · 2020-04-14FDA Approved: VENLAFAXINE — Supplemental Application (BluePoint Laboratories)
The FDA approved a supplemental application for venlafaxine by BluePoint Laboratories, expanding its generic availability.
-
FDA approval · 2020-04-14FDA Approved: VENLAFAXINE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for Venlafaxine hydrochloride (generic Venlafaxine) by Aurobindo Pharma Limited.
-
FDA approval · 2020-04-10FDA Approved: VENLAFAXINE — Supplemental Application (Alembic Pharmaceuticals Inc.)
FDA approved a supplemental application for venlafaxine from Alembic Pharmaceuticals.
-
FDA approval · 2020-04-03FDA Approved: LYRICA CR — Supplemental Application (Viatris Specialty LLC)
FDA approved a supplemental NDA for LYRICA CR (pregabalin) submitted by Viatris Specialty LLC, indicating a regulatory approval of a supplem…
-
FDA approval · 2020-03-23FDA Approved: PREGABALIN — Original Application (Creekwood Pharmaceuticals LLC)
FDA approves Creekwood Pharmaceuticals LLC's Original Application (ANDA) for pregabalin, enabling a generic version of the drug. This action…
-
FDA approval · 2020-03-17FDA Approved: OXAZEPAM — Supplemental Application (TruPharma, LLC)
FDA approved a supplemental application for Oxazepam from TruPharma, LLC.
-
FDA approval · 2020-03-12FDA Approved: VENLAFAXINE HYDROCHLORIDE — Original Application (Advagen Pharma Ltd.)
FDA approved the original application for venlafaxine hydrochloride by Advagen Pharma Ltd., authorizing a generic version of this antidepres…
-
FDA approval · 2020-02-21FDA Approved: BUSPIRONE HYDROCHLORIDE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for Buspirone Hydrochloride by Aurobindo Pharma Limited, authorizing continued manufacture and suppl…
-
FDA approval · 2020-02-04FDA Approved: BUSPIRONE HYDROCHLORIDE — Supplemental Application (Radha Pharmaceuticals, Inc.)
The FDA approved a supplemental application for buspirone hydrochloride submitted by Radha Pharmaceuticals, Inc., under an approved ANDA.
-
CLINICAL_TRIALS trial_result · 2020-01-07Clinical Trial Update: Tandospirone Citrate in the Treatment of Patients With Generalized Anxiety Disorder [Phase 4]
Phase 4 trial update for tandospirone citrate in generalized anxiety disorder has completed.
-
FDA approval · 2019-12-31FDA Approved: ALPRAZOLAM — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for Alprazolam from Sandoz Inc, confirming approval of a generic Alprazolam product.
-
FDA approval · 2019-12-31FDA Approved: ALPRAZOLAM — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for Alprazolam from Aurobindo Pharma Limited.
-
FDA approval · 2019-12-31FDA Approved: ALPRAZOLAM — Supplemental Application (Actavis Pharma, Inc.)
FDA approves Actavis Pharma, Inc.'s supplemental application for a generic alprazolam product, confirming approval of the supplemental submi…
-
CLINICAL_TRIALS trial_result · 2019-12-18Clinical Trial Update: Safety, Efficacy and Tolerability of Vilazodone in (GAD) Generalized Anxiety Disorder [Phase 3]
Phase 3 trial update evaluating safety, efficacy, and tolerability of vilazodone for generalized anxiety disorder has completed with posted …
-
CLINICAL_TRIALS trial_result · 2019-12-18Clinical Trial Update: Safety, Efficacy and Tolerability of Vilazodone in Patients With Generalized Anxiety Disorder [Phase 3]
Phase 3 clinical trial evaluating vilazodone for generalized anxiety disorder assessing safety, efficacy, and tolerability.
-
CLINICAL_TRIALS trial_result · 2019-12-18Clinical Trial Update: Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder [Phase 3]
Phase 3 clinical trial updating safety, efficacy, and tolerability of vilazodone in generalized anxiety disorder (GAD).
-
FDA approval · 2019-12-13FDA Approved: DULOXETINE — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental abbreviated new drug application for duloxetine hydrochloride from Aurobindo Pharma Limited (ANDA 090778), e…
-
CLINICAL_TRIALS trial_result · 2019-11-25Clinical Trial Update: The Effects of Emotional Exposure on State Anxiety [NA]
A completed clinical trial studying the effects of emotional exposure on state anxiety in Generalized Anxiety Disorder; results posted in 20…